Northstar Emergency Management, LLC
Small business focused on development of antibody-fragment-based biodefense countermeasures intended for rapid point-of-incident diagnosis and treatment. The organization pursues partnerships for antibody design, testing, and scaled production and engages with government and research stakeholders on program development.
Industries
N/A
Nr. of Employees
small (1-50)
Northstar Emergency Management, LLC
Products
Antibody fragment-based point-of-incident countermeasure (concept)
A concept for using engineered antibody fragments as on-site diagnostics and therapeutics intended to provide rapid diagnosis and immediate treatment in bioterrorism or biodefense events.
Antibody fragment-based point-of-incident countermeasure (concept)
A concept for using engineered antibody fragments as on-site diagnostics and therapeutics intended to provide rapid diagnosis and immediate treatment in bioterrorism or biodefense events.
Services
Collaborative partnerships and coordination with external organizations for antibody design, testing workflows, and planning for scaled biologics production.
Collaborative partnerships and coordination with external organizations for antibody design, testing workflows, and planning for scaled biologics production.
Expertise Areas
- Biodefense and bioterrorism countermeasure development
- Antibody fragment engineering
- Rapid point-of-incident diagnostics and therapeutic concepts
- Partnership development and collaboration management
Key Technologies
- Antibody fragment (Fab) engineering
- Point-of-care / point-of-incident diagnostic concepts
- Rapid therapeutic deployment using antibody fragments
- Biologics scale-up planning
News & Updates
Engagement with a government biodefense funding agency via a Tech Watch Light call.
Presentation/pitch of the antibody fragment countermeasure concept at an innovation conference.
Poster presentation describing the antibody fragment approach at a Medical Technology Enterprise Consortium meeting in Richmond, VA.
Execution of a non-disclosure agreement with an academic institution to support collaboration.
Engagement with a government biodefense funding agency via a Tech Watch Light call.
Presentation/pitch of the antibody fragment countermeasure concept at an innovation conference.
Poster presentation describing the antibody fragment approach at a Medical Technology Enterprise Consortium meeting in Richmond, VA.
Execution of a non-disclosure agreement with an academic institution to support collaboration.